SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Porte RJ, Bontempo FA, Knot EA, Lewis JH, Kang YG, Starzl TE. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989;47:978-984.
  • 2
    Mallett SV, Cox D, Burroughs AK, Rolles K. Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. Lancet 1990;336:886-887.
  • 3
    Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 2000;355:1303-1309.
  • 4
    Liu CM, Chen J, Wang XH. Requirements for transfusion and postoperative outcomes in orthotopic liver transplantation: a meta-analysis on aprotinin. World J Gastroenterol 2008;14:1425-1429.
  • 5
    Mangano DT, Tudor IC, Dietzel C; for Multicenter Study of Perioperative Ischemia Research Group and Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-365.
  • 6
    Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al.; for BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-2331.
  • 7
    Trzebicki J, Kosieradzki M, Flakiewicz E, Kuzminska G, Wasiak D, Pacholczyk M, et al. Detrimental effect of aprotinin ban on amount of blood loss during liver transplantation: single-center experience. Transplant Proc 2011;43:1725-1727.
  • 8
    Ickx BE, van der Linden PJ, Melot C, Wijns W, de Pauw L, Vandestadt J, et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation. Transfusion 2006;46:595-605.
  • 9
    Massicotte L, Denault AY, Beaulieu D, Thibeault L, Hevesi Z, Roy A. Aprotinin versus tranexamic acid during liver transplantation: impact on blood product requirements and survival. Transplantation 2011;91:1273-1278.
  • 10
    Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2007;7:185-194.
  • 11
    Baubillier E, Cherqui D, Dominique C, Khalil M, Bonnet F, Fagniez PL, Duvaldestin P. A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation 1994;57:1664-1666.
  • 12
    Ramsay MA, Randall HB, Burton EC. Intravascular thrombosis and thromboembolism during liver transplantation: antifibrinolytic therapy implicated? Liver Transpl 2004;10:310-314.
  • 13
    Warnaar N, Mallett SV, de Boer MT, Rolando N, Burroughs AK, Nijsten MW, et al. The impact of aprotinin on renal function after liver transplantation: an analysis of 1,043 patients. Am J Transplant 2007;7:2378-2387.
  • 14
    Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-1291.
  • 15
    Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease. Clin Liver Dis 2009;13:21-31.
  • 16
    Porte RJ, Blauw E, Knot EA, de Maat MP, de Ruiter C, Minke Bakker C, Terpstra OT. Role of the donor liver in the origin of platelet disorders and hyperfibrinolysis in liver transplantation. J Hepatol 1994;21:592-600.
  • 17
    Warnaar N, Mallett SV, Klinck JR, de Boer MT, Rolando N, Burroughs AK, et al. Aprotinin and the risk of thrombotic complications after liver transplantation: a retrospective analysis of 1492 patients. Liver Transpl 2009;15:747-753.
  • 18
    Dalmau A, Sabaté A, Acosta F, Garcia-Huete L, Koo M, Sansano T, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000;91:29-34.
  • 19
    Görlinger K. Coagulation management during liver transplantation [in German]. Hamostaseologie 2006;26(suppl 1):S64-S76.
  • 20
    Broomhead RH, Patel S, Fernando B, O'Beirne J, Mallett S. Resource implications of expanding the use of donation after circulatory determination of death in liver transplantation. Liver Transpl 2012;18:771-778.
  • 21
    Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR. Methods to decrease blood loss and transfusion requirements for liver transplantation. Cochrane Database Syst Rev 2011:CD009052.
  • 22
    Molenaar IQ, Legnani C, Groenland TH, Palareti G, Begliomini B, Terpstra OT, Porte RJ. Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic, effect. Liver Transpl 2001;7:896-903.